Ibrutinib (I) is the first-in-class covalent BTK inhibitor (cBTKi), which disrupts the B-cell receptor (BCR) signaling pathway, thereby inhibiting the survival and proliferation of CLL cells. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.